COVID-19: Covaxin gets shelf-life extension up to 12 months

By: |
Updated: November 03, 2021 5:42 PM

Bharat Biotech was initially given permission for the sale and distribution of Covaxin with a shelf life of six months, which was later extended to nine months, a company spokesperson told PTI.

bharat biotech, Covaxin, Oman's list of approved COVID-19 vaccines, Embassy of India, Muscat, Civil Aviation Authority, Embassy of India, MuscatThe shelf life extension has been communicated to "our stakeholders," it added. (File)

Vaccine maker Bharat Biotech on Wednesday said the Central Drugs Standard Control Organisation (CDSCO) has approved the extension of shelf life of its COVID-19 vaccine Covaxin up to 12 months from the date of manufacture.

Bharat Biotech was initially given permission for the sale and distribution of Covaxin with a shelf life of six months, which was later extended to nine months, a company spokesperson told PTI.

“The CDSCO has approved the extension of shelf life of Covaxin up to 12 months, from the date of manufacture. This approval of shelf life extension is based on the availability of additional stability data, which was submitted to CDSCO,” Bharat Biotech said in a tweet.

The shelf life extension has been communicated to “our stakeholders,” it added.

The approval for the extension of shelf life of the vaccine comes ahead of crucial World Health Organisation (WHO) meeting for a final risk-benefit assessment for the emergency use listing (EUL) for the vaccine.

The WHO’s Technical Advisory Group for EUL last week had sought additional clarifications from Bharat Biotech for Covaxin.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Serum Institute plans to cut monthly production of Covishield by 50%
2COVID-19: Serum Institute of India may halve Covishield monthly production amid demand slump
3The top myths about Chronic Obstructive Pulmonary Disease